CEL-SCI Corporation
Virginia, United States · Biotechnology, Healthcare, Health Care · 43 employees
CEL-SCI is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company’s lead investigational therapy Multikine completed a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company has received Orphan Drug Status from the FDA. The Company will be commencing a confirmatory trial
Funding history
- Funding Round — $10.8M — Jul 2024
- Funding Round — Undisclosed — Jul 2017
Recent signals
- May 11, 2026: CEL-SCI Partners with Amarox for the Distribution and Revenue Sharing of Multikine in Saudi Arabia.
- Jul 11, 2025: CEL-SCI Corporation Enters Partnership with Saudi Pharmaceutical Company for Cancer Drug Multikine.
- Dec 12, 2024: Launched CEL-SCI Corporation Announces Strong Biological Rationale for Multikine in Head and Neck Cancer Study
- Oct 01, 2024: CEL-SCI Renews Partnership with Ergomed for FDA Registration Study of Multikine in Head and Neck Cancer
- Jul 29, 2024: Raised $10.8M
- Jul 17, 2017: Raised Undisclosed
See plans & pricing → Track CEL-SCI Corporation’s funding, hiring, and signals — with verified contacts — on Fundz.